Preventive migraine treatment with eptinezumab reduced acute headache medication and headache frequency to below diagnostic thresholds in patients with chronic migraine and medication-overuse headache

RECOMMENDED

Migraine and Headache

Efficacy, tolerability, and safety of eptinezumab in patients with a dual diagnosis of chronic migraine and medication-overuse headache: Subgroup analysis of PROMISE-2

★ 2 Recommended by Prof. Dr Claudio Gobbi, Faculty Member

Headache

Diener HC, Marmura MJ, Tepper SJ, Cowan R, Starling AJ, Diamond ML, Hirman J, Mehta L, Brevig T, Sperling B, Cady R

doi: 10.1111/head.14036

RECOMMENDED

Migraine and Headache

Acute withdrawal and botulinum toxin A in chronic migraine with medication overuse: a double-blind randomized controlled trial

Brain.

Pijpers JA, Kies DA, Louter MA, van Zwet EW, Ferrari MD, Terwindt GM

doi: 10.1093/

Migraine and Headache

Effects of fremanezumab on the use of acute headache medication and associated symptoms of migraine in patients with episodic migraine

Cephalalgia.

Brandes JL, Kudrow D, Yeung PP, Sakai F, Aycardi E, Blankenbiller T, Grozinski-Wolff M, Yang R, Ma Y

doi: 10.1177/0333102419885905.

Migraine and Headache

A prospective pilot study of the effect on catecholamines of mindfulness training vs pharmacological prophylaxis in patients with chronic migraine and medication overuse headache

Cephalalgia.

Grazzi L, Raggi A, D'Amico D, Sansone E, Leonardi M, Andrasik F, Gucciardi A, Guido D, D'Andrea G

doi: 10.1177/0333102418801584.

Migraine and Headache

Discontinuation of Acute Prescription Medication for Migraine: Results From the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study

Headache.

Lipton RB, Hutchinson S, Ailani J, Reed ML, Fanning KM, Manack Adams A, Buse DC

doi: 10.1111/head.13642.

RECOMMENDED

Migraine and Headache

A Real-World Analysis of Patient Characteristics, Treatment Patterns, and Level of Impairment in Patients With Migraine Who are Insufficient Responders vs Responders to Acute Treatment

★ 2 Recommended by Prof. Dr Claudio Gobbi, Faculty Member

Headache.

Lombard L, Ye W, Nichols R, Jackson J, Cotton S, Joshi S

doi: 10.1111/head.13835.

Migraine and Headache

Understanding the migraine treatment landscape prior to the introduction of calcitonin gene-related peptide inhibitors: Results from the Assessment of TolerabiliTy and Effectiveness in MigrAINe Patients using Preventive Treatment (ATTAIN) study

Headache

Kawata AK, Shah N, Poon JL, Shaffer S, Sapra S, Wilcox TK, Shah S, Tepper SJ, Dodick DW, Lipton RB

doi: 10.1111/head.14053

RECOMMENDED

Migraine and Headache

A Randomized Trial to Evaluate OnabotulinumtoxinA for Prevention of Headaches in Adolescents With Chronic Migraine

★ 1 Recommended by Prof. Dr Claudio Gobbi, Faculty Member

Headache.

Winner PK, Kabbouche M, Yonker M, Wangsadipura V, Lum A, Brin MF

doi: 10.1111/head.13754.

Migraine and Headache

Improvements in quality of life and work productivity with up to 6 months of fremanezumab treatment in patients with episodic and chronic migraine and documented inadequate response to 2 to 4 classes of migraine-preventive medications in the phase 3b FOCUS study

Headache

Spierings ELH, Ning X, Ramirez Campos V, Cohen JM, Barash S, Buse DC

doi: 10.1111/head.14196

Related content

Efficacy, tolerability, and safety of eptinezumab in patients with a dual diagnosis of chronic migraine and medication-overuse headache: Subgroup analysis of PROMISE-2

Acute withdrawal and botulinum toxin A in chronic migraine with medication overuse: a double-blind randomized controlled trial

Effects of fremanezumab on the use of acute headache medication and associated symptoms of migraine in patients with episodic migraine

A prospective pilot study of the effect on catecholamines of mindfulness training vs pharmacological prophylaxis in patients with chronic migraine and medication overuse headache

Discontinuation of Acute Prescription Medication for Migraine: Results From the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study

A Real-World Analysis of Patient Characteristics, Treatment Patterns, and Level of Impairment in Patients With Migraine Who are Insufficient Responders vs Responders to Acute Treatment

Understanding the migraine treatment landscape prior to the introduction of calcitonin gene-related peptide inhibitors: Results from the Assessment of TolerabiliTy and Effectiveness in MigrAINe Patients using Preventive Treatment (ATTAIN) study

A Randomized Trial to Evaluate OnabotulinumtoxinA for Prevention of Headaches in Adolescents With Chronic Migraine

Improvements in quality of life and work productivity with up to 6 months of fremanezumab treatment in patients with episodic and chronic migraine and documented inadequate response to 2 to 4 classes of migraine-preventive medications in the phase 3b FOCUS study